Not currently recruiting at UCSF
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Tina Bhutani
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Tina Bhutani
Assistant Professor, Dermatology.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Galderma R&D
- ID
- NCT03989206
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated